Meet Zylidac: A New CDMO with Forty-Plus Years of Experience
Zylidac is a new CDMO subsidiary of India-based biopharma company Zydus Lifesciences. Although launched in early 2026, the Zylidac team has over four decades of experience shepherding biologic therapeutics, including antibodies, bispecifics, and fusion proteins, from preclinical development to commercial production. At its state-of-the-art facility in Emeryville, CA, Zylidac supports clients from cell-line development through fill/finish, labeling, packaging, and distribution.
In this Q and A, three leaders of the Zylidac team, Al Dadson, Chief Manufacturing Officer, Steve Lavezoli, Chief Commercial Officer, and Mandy Sharma, Vice President, Technical Operations, discuss the genesis of the company and what sets it apart from other CDMOs, including its extensive experience working with many different clinical and commercial products, the longevity of the team, their experience on the sponsor side of sponsor-CDMO relationships, and its ability to support projects across the entire product lifecycle.